UnitedHealth could buy Advisory Board’s healthcare division

John Gregory | | Health Exec | Economics

As a part of a deal to split up consulting and research firm The Advisory Board Company, its healthcare business could be purchased by UnitedHealth, the nation’s largest health insurer.

Bloomberg reported a potential price tag only Advisory Board’s education unit, which makes up a third of the company’s revenue but could be sold to Vista Equity Partners for $1.5 billion. The anonymous sources quoted by Bloomberg said this isn’t a done deal and any confirmation may not come until August due to the “complicated structure” of the transaction.

Both Advisory Board and UnitedHealth declined to comment.

Read the full article at the link below:

UnitedHealth, Vista Said Near Deal to Split Advisory Board

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

American Heart Association highlights importance of NIH as battle over Trump funding cuts continues
Federal judge sides with FTC; case against PBMs to move forward
UnitedHealth pushes back against shareholder transparency proposal
Thousands of staff cut from federal health agencies, including CDC and VA
Nonprofit academic hospital receives criticism after running Super Bowl ad
HeartBeam raising $10M for FDA-cleared health tech with public offering

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”